

FIRST REGULAR SESSION

HOUSE BILL NO. 551

96TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES SCHIEFFER (Sponsor) AND KIRKTON (Co-sponsor).

1399L.011

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with an existing penalty provision.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

(g) Alpha-methylfentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxeridine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacetylmorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;

- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myorphine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;

- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
- 110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) D e x a n a b i n o l ,
- 115 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10
- 116 a-tetrahydrobenzo[c]chromen-1-ol;
- 117 (s) Diethyltryptamine;
- 118 (t) Dimethyltryptamine;
- 119 (u) 5-methoxy-N,N-diisopropyltryptamine;
- 120 (v) Ibogaine;
- 121 (w) Indole, or 1-butyl-3(1-naphthoyl)indole;
- 122 (x) Indole, or 1-pentyl-3(1-naphthoyl)indole;
- 123 (y) Lysergic acid diethylamide;
- 124 (z) Marijuana or marihuana;
- 125 (aa) Mescaline;

- 126 (bb) Parahexyl;
- 127 (cc) Peyote, to include all parts of the plant presently classified botanically as
128 *Lophophora Williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any
129 part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of
130 the plant, its seed or extracts;
- 131 (dd) Phenol, CP 47, 497 & homologues, or
132 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain n=5, and
133 homologues where side chain n=4,6, or 7;
- 134 (ee) N-ethyl-3-piperidyl benzilate;
- 135 (ff) N-methyl-3-piperidyl benzilate;
- 136 (gg) Psilocybin;
- 137 (hh) Psilocyn;
- 138 (ii) Tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis* (cannabis
139 plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in
140 the resinous extractives of such plant, or synthetic substances, derivatives, and their isomers with
141 similar chemical structure and pharmacological activity to those substances contained in the
142 plant, such as the following:
- 143 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 144 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 145 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 146 d. Any compounds of these structures, regardless of numerical designation of atomic
147 positions covered;
- 148 (jj) Ethylamine analog of phencyclidine;
- 149 (kk) Pyrrolidine analog of phencyclidine;
- 150 (ll) Thiophene analog of phencyclidine;
- 151 (mm) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 152 (nn) *Salvia divinorum*;
- 153 (oo) Salvinorin A;
- 154 (5) Any material, compound, mixture or preparation containing any quantity of the
155 following substances having a depressant effect on the central nervous system, including their
156 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
157 isomers is possible within the specific chemical designation:
- 158 (a) Gamma-hydroxybutyric acid;
- 159 (b) Mecloqualone;
- 160 (c) Methaqualone;

161 (6) Any material, compound, mixture or preparation containing any quantity of the
162 following substances having a stimulant effect on the central nervous system, including their
163 salts, isomers and salts of isomers:

164 (a) Aminorex;

165 (b) N-benzylpiperazine;

166 (c) Cathinone;

167 (d) Fenethylamine;

168 (e) Methcathinone;

169 (f) **Methylenedioxypropylamphetamine or [(MDPV) (1-(1,3-Benzodioxol-5-yl)-2-(1-
170 pyrrolidinyl)-1-pentanone)];**

171 [(f)] (g) (+, -) cis-4-methylaminorex
172 ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);

173 [(g)] (h) N-ethylamphetamine;

174 [(h)] (i) N,N-dimethylamphetamine;

175 (7) A temporary listing of substances subject to emergency scheduling under federal law
176 shall include any material, compound, mixture or preparation which contains any quantity of the
177 following substances:

178 (a) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers,
179 salts and salts of isomers;

180 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
181 optical isomers, salts and salts of isomers;

182 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
183 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
184 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

185 3. The department of health and senior services shall place a substance in Schedule II
186 if it finds that:

187 (1) The substance has high potential for abuse;

188 (2) The substance has currently accepted medical use in treatment in the United States,
189 or currently accepted medical use with severe restrictions; and

190 (3) The abuse of the substance may lead to severe psychic or physical dependence.

191 4. The controlled substances listed in this subsection are included in Schedule II:

192 (1) Any of the following substances whether produced directly or indirectly by extraction
193 from substances of vegetable origin, or independently by means of chemical synthesis, or by
194 combination of extraction and chemical synthesis:

195 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
196 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine,
197 nalmeferene, naloxone and naltrexone, and their respective salts but including the following:

- 198 a. Raw opium;
- 199 b. Opium extracts;
- 200 c. Opium fluid;
- 201 d. Powdered opium;
- 202 e. Granulated opium;
- 203 f. Tincture of opium;
- 204 g. Codeine;
- 205 h. Ethylmorphine;
- 206 i. Etorphine hydrochloride;
- 207 j. Hydrocodone;
- 208 k. Hydromorphone;
- 209 l. Metopon;
- 210 m. Morphine;
- 211 n. Oxycodone;
- 212 o. Oxymorphone;
- 213 p. Thebaine;

214 (b) Any salt, compound, derivative, or preparation thereof which is chemically
215 equivalent or identical with any of the substances referred to in this subdivision, but not
216 including the isoquinoline alkaloids of opium;

217 (c) Opium poppy and poppy straw;

218 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
219 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
220 with any of these substances, but not including decocainized coca leaves or extractions which
221 do not contain cocaine or ecgonine;

222 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
223 or powder form which contains the phenanthrene alkaloids of the opium poppy);

224 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
225 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
226 the specific chemical designation, dextrorphan and levopropoxyphene excepted:

- 227 (a) Alfentanil;
- 228 (b) Alphaprodine;
- 229 (c) Anileridine;
- 230 (d) Bezitramide;

- 231 (e) Bulk dextropropoxyphene;
232 (f) Carfentanil;
233 (g) Dihydrocodeine;
234 (h) Diphenoxylate;
235 (i) Fentanyl;
236 (j) Isomethadone;
237 (k) Levo-alphaacetylmethadol;
238 (l) Levomethorphan;
239 (m) Levorphanol;
240 (n) Metazocine;
241 (o) Methadone;
242 (p) Meperidine;
243 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
244 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
245 acid;
246 (s) Pethidine (meperidine);
247 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
248 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
249 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
250 (w) Phenazocine;
251 (x) Piminodine;
252 (y) Racemethorphan;
253 (z) Racemorphan;
254 (aa) Remifentanil;
255 (bb) Sufentanil;
256 (cc) Tapentadol;
257 (3) Any material, compound, mixture, or preparation which contains any quantity of the
258 following substances having a stimulant effect on the central nervous system:
259 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
260 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
261 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
262 (d) Phenmetrazine and its salts;
263 (e) Methylphenidate;
264 (4) Any material, compound, mixture, or preparation which contains any quantity of the
265 following substances having a depressant effect on the central nervous system, including its salts,

266 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
267 is possible within the specific chemical designation:

268 (a) Amobarbital;

269 (b) Glutethimide;

270 (c) Pentobarbital;

271 (d) Phencyclidine;

272 (e) Secobarbital;

273 (5) Any material or compound which contains any quantity of nabilone;

274 (6) Any material, compound, mixture, or preparation which contains any quantity of the
275 following substances:

276 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;

277 (b) Immediate precursors to phencyclidine (PCP):

278 a. 1-phenylcyclohexylamine;

279 b. 1-piperidinocyclohexanecarbonitrile (PCC);

280 (7) Any material, compound, mixture, or preparation which contains any quantity of the
281 following alkyl nitrites:

282 (a) Amyl nitrite;

283 (b) Butyl nitrite.

284 5. The department of health and senior services shall place a substance in Schedule III
285 if it finds that:

286 (1) The substance has a potential for abuse less than the substances listed in Schedules
287 I and II;

288 (2) The substance has currently accepted medical use in treatment in the United States;
289 and

290 (3) Abuse of the substance may lead to moderate or low physical dependence or high
291 psychological dependence.

292 6. The controlled substances listed in this subsection are included in Schedule III:

293 (1) Any material, compound, mixture, or preparation which contains any quantity of the
294 following substances having a potential for abuse associated with a stimulant effect on the
295 central nervous system:

296 (a) Benzphetamine;

297 (b) Chlorphentermine;

298 (c) Clortermine;

299 (d) Phendimetrazine;

300 (2) Any material, compound, mixture or preparation which contains any quantity or salt
301 of the following substances or salts having a depressant effect on the central nervous system:

- 302 (a) Any material, compound, mixture or preparation which contains any quantity or salt
303 of the following substances combined with one or more active medicinal ingredients:
- 304 a. Amobarbital;
305 b. Secobarbital;
306 c. Pentobarbital;
- 307 (b) Any suppository dosage form containing any quantity or salt of the following:
- 308 a. Amobarbital;
309 b. Secobarbital;
310 c. Pentobarbital;
- 311 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
312 salt;
- 313 (d) Chlorhexadol;
314 (e) Embutramide;
315 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
316 a drug product for which an application has been approved under Section 505 of the federal
317 Food, Drug, and Cosmetic Act;
- 318 (g) Ketamine, its salts, isomers, and salts of isomers;
319 (h) Lysergic acid;
320 (i) Lysergic acid amide;
321 (j) Methyprylon;
322 (k) Sulfondiethylmethane;
323 (l) Sulfonethylmethane;
324 (m) Sulfonmethane;
325 (n) Tiletamine and zolazepam or any salt thereof;
- 326 (3) Nalorphine;
- 327 (4) Any material, compound, mixture, or preparation containing limited quantities of any
328 of the following narcotic drugs or their salts:
- 329 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
330 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
331 of opium;
- 332 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
333 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
334 therapeutic amounts;
- 335 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
336 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
337 isoquinoline alkaloid of opium;

338 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
339 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
340 ingredients in recognized therapeutic amounts;

341 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
342 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
343 recognized therapeutic amounts;

344 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
345 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
346 ingredients in recognized therapeutic amounts;

347 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
348 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
349 active nonnarcotic ingredients in recognized therapeutic amounts;

350 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
351 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
352 amounts;

353 (5) Any material, compound, mixture, or preparation containing any of the following
354 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

355 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
356 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
357 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
358 expressly intended for administration through implants to cattle or other nonhuman species and
359 which has been approved by the Secretary of Health and Human Services for that administration.
360 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
361 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
362 meaning of this [paragraph] **subdivision**. Unless specifically excepted or unless listed in another
363 schedule, any material, compound, mixture or preparation containing any quantity of the
364 following substances, including its salts, esters and ethers:

- 365 (a) $3\beta,17$ -dihydroxy- 5α -androstane;
366 (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
367 (c) 5α -androstan- $3,17$ -dione;
368 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
369 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
370 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
371 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
372 (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
373 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);

- 374 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 375 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 376 (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);
- 377 (m) Boldione;
- 378 (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 379 (o) Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
- 380 (p) D e h y d r o c h l o r o m e t h y l t e s t o s t e r o n e
- 381 (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-dien-3-one);
- 382 (q) Desoxymethyltestosterone;
- 383 (r) Δ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-3-one);
- 384 (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- 385 (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
- 386 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- 387 (v) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
- 388 (w) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
- 389 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furazan);
- 390 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 391 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 392 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 393 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
- 394 (cc) Mesterolone (1 α methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- 395 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- 396 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 397 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- 398 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
- 399 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
- 400 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 401 (j j) 1 7 α - m e t h y l - 4 - h y d r o x y n a n d r o l o n e
- 402 (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);
- 403 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- 404 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
- 405 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- 406 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- 407 (o o) 1 7 α - m e t h y l - Δ 1 - d i h y d r o t e s t o s t e r o n e
- 408 (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
- 409 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);

- 410 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
 411 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
 412 (ss) 19-nor-4,9(10)-androstadienedione;
 413 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
 414 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
 415 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
 416 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 417 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
 418 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
 419 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
 420 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
 421 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
 422 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
 423 (d d d) O x y m e t h a l o n e
 424 (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-one);
 425 (eee) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
 426 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
 427 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
 428 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
 429 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
 430 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
 431 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
 432 subdivision, except an anabolic steroid which is expressly intended for administration through
 433 implants to cattle or other nonhuman species and which has been approved by the Secretary of
 434 Health and Human Services for that administration;
 435 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
 436 United States Food and Drug Administration approved drug product;
 437 (8) The department of health and senior services may except by rule any compound,
 438 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
 439 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
 440 195.320 if the compound, mixture, or preparation contains one or more active medicinal
 441 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
 442 admixtures are included therein in combinations, quantity, proportion, or concentration that
 443 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
 444 the central nervous system.

445 7. The department of health and senior services shall place a substance in Schedule IV
446 if it finds that:

447 (1) The substance has a low potential for abuse relative to substances in Schedule III;

448 (2) The substance has currently accepted medical use in treatment in the United States;

449 and

450 (3) Abuse of the substance may lead to limited physical dependence or psychological
451 dependence relative to the substances in Schedule III.

452 8. The controlled substances listed in this subsection are included in Schedule IV:

453 (1) Any material, compound, mixture, or preparation containing any of the following
454 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
455 as set forth below:

456 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
457 of atropine sulfate per dosage unit;

458 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
459 propionoxybutane);

460 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
461 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
462 upon the compound, mixture or preparation valuable medicinal qualities other than those
463 possessed by the narcotic drug alone:

464 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
465 one hundred grams;

466 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
467 or per one hundred grams;

468 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
469 or per one hundred grams;

470 (2) Any material, compound, mixture or preparation containing any quantity of the
471 following substances, including their salts, isomers, and salts of isomers whenever the existence
472 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

473 (a) Alprazolam;

474 (b) Barbital;

475 (c) Bromazepam;

476 (d) Camazepam;

477 (e) Chloral betaine;

478 (f) Chloral hydrate;

479 (g) Chlordiazepoxide;

480 (h) Clobazam;

- 481 (i) Clonazepam;
- 482 (j) Clorazepate;
- 483 (k) Clotiazepam;
- 484 (l) Cloxazolam;
- 485 (m) Delorazepam;
- 486 (n) Diazepam;
- 487 (o) Dichloralphenazone;
- 488 (p) Estazolam;
- 489 (q) Ethchlorvynol;
- 490 (r) Ethinamate;
- 491 (s) Ethyl loflazepate;
- 492 (t) Fludiazepam;
- 493 (u) Flunitrazepam;
- 494 (v) Flurazepam;
- 495 (w) Fospropofol;
- 496 (x) Halazepam;
- 497 (y) Haloxazolam;
- 498 (z) Ketazolam;
- 499 (aa) Loprazolam;
- 500 (bb) Lorazepam;
- 501 (cc) Lormetazepam;
- 502 (dd) Mebutamate;
- 503 (ee) Medazepam;
- 504 (ff) Meprobamate;
- 505 (gg) Methohexital;
- 506 (hh) Methylphenobarbital (mephobarbital);
- 507 (ii) Midazolam;
- 508 (jj) Nimetazepam;
- 509 (kk) Nitrazepam;
- 510 (ll) Nordiazepam;
- 511 (mm) Oxazepam;
- 512 (nn) Oxazolam;
- 513 (oo) Paraldehyde;
- 514 (pp) Petrichloral;
- 515 (qq) Phenobarbital;
- 516 (rr) Pinazepam;

- 517 (ss) Prazepam;
- 518 (tt) Quazepam;
- 519 (uu) Temazepam;
- 520 (vv) Tetrazepam;
- 521 (ww) Triazolam;
- 522 (xx) Zaleplon;
- 523 (yy) Zolpidem;
- 524 (zz) Zopiclone;
- 525 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 526 following substance including its salts, isomers and salts of isomers whenever the existence of
- 527 such salts, isomers and salts of isomers is possible: fenfluramine;
- 528 (4) Any material, compound, mixture or preparation containing any quantity of the
- 529 following substances having a stimulant effect on the central nervous system, including their
- 530 salts, isomers and salts of isomers:
- 531 (a) Cathine ((+)-norpseudoephedrine);
- 532 (b) Diethylpropion;
- 533 (c) Fencamfamin;
- 534 (d) Fenproporex;
- 535 (e) Mazindol;
- 536 (f) Mefenorex;
- 537 (g) Modafinil;
- 538 (h) Pemoline, including organometallic complexes and chelates thereof;
- 539 (i) Phentermine;
- 540 (j) Pipradrol;
- 541 (k) Sibutramine;
- 542 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 543 (5) Any material, compound, mixture or preparation containing any quantity of the
- 544 following substance, including its salts:
- 545 (a) Butorphanol;
- 546 (b) Pentazocine;
- 547 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
- 548 is the only active medicinal ingredient;
- 549 (7) The department of health and senior services may except by rule any compound,
- 550 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
- 551 subsection from the application of all or any part of sections 195.010 to 195.320 if the
- 552 compound, mixture, or preparation contains one or more active medicinal ingredients not having

553 a depressant effect on the central nervous system, and if the admixtures are included therein in
554 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
555 substances which have a depressant effect on the central nervous system.

556 9. The department of health and senior services shall place a substance in Schedule V
557 if it finds that:

558 (1) The substance has low potential for abuse relative to the controlled substances listed
559 in Schedule IV;

560 (2) The substance has currently accepted medical use in treatment in the United States;
561 and

562 (3) The substance has limited physical dependence or psychological dependence liability
563 relative to the controlled substances listed in Schedule IV.

564 10. The controlled substances listed in this subsection are included in Schedule V:

565 (1) Any compound, mixture or preparation containing any of the following narcotic
566 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
567 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
568 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
569 qualities other than those possessed by the narcotic drug alone:

570 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
571 twenty-five micrograms of atropine sulfate per dosage unit;

572 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
573 one hundred grams;

574 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
575 micrograms of atropine sulfate per dosage unit;

576 (2) Any material, compound, mixture or preparation which contains any quantity of the
577 following substance having a stimulant effect on the central nervous system including its salts,
578 isomers and salts of isomers: pyrovalerone;

579 (3) Any compound, mixture, or preparation containing any detectable quantity of
580 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
581 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
582 isomers, or salts of optical isomers;

583 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
584 material, compound, mixture, or preparation which contains any quantity of the following
585 substances having a depressant effect on the central nervous system, including its salts:

586 (a) Lacosamide;

587 (b) Pregabalin.

588 11. If any compound, mixture, or preparation as specified in subdivision (3) of
589 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
590 prescription:

591 (1) All packages of any compound, mixture, or preparation containing any detectable
592 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
593 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
594 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
595 registered pharmacy technician; and

596 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
597 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
598 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
599 shall be at least eighteen years of age; and

600 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
601 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
602 or preparation to furnish suitable photo identification that is issued by a state or the federal
603 government or a document that, with respect to identification, is considered acceptable and
604 showing the date of birth of the person;

605 (4) The seller shall deliver the product directly into the custody of the purchaser.

606 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
607 implement and maintain an electronic log of each transaction. Such log shall include the
608 following information:

609 (1) The name, address, and signature of the purchaser;

610 (2) The amount of the compound, mixture, or preparation purchased;

611 (3) The date and time of each purchase; and

612 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
613 technician who dispensed the compound, mixture, or preparation to the purchaser.

614 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
615 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
616 transmission methods and frequency established by the department by regulation;

617 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
618 greater than those specified in this chapter.

619 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
620 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
621 where the public is not permitted.

622 16. Any person who knowingly or recklessly violates the provisions of subsections 11
623 to 15 of this section is guilty of a class A misdemeanor.

624 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
625 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
626 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
627 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
628 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

629 18. The manufacturer of a drug product or another interested party may apply with the
630 department of health and senior services for an exemption from this section. The department of
631 health and senior services may grant an exemption by rule from this section if the department
632 finds the drug product is not used in the illegal manufacture of methamphetamine or other
633 controlled or dangerous substances. The department of health and senior services shall rely on
634 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
635 proposed product can be used to manufacture illicit controlled substances.

636 19. The department of health and senior services shall revise and republish the schedules
637 annually.

638 20. The department of health and senior services shall promulgate rules under chapter
639 536 regarding the security and storage of Schedule V controlled substances, as described in
640 subdivision (3) of subsection 10 of this section, for distributors as registered by the department
641 of health and senior services.

642 21. Logs of transactions required to be kept and maintained by this section and section
643 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
644 the person whose transactions are recorded in the logs.